Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ironwood Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.57|
|52-week range||$8.63 - $13.65|
|50-day moving average||$12.49|
|200-day moving average||$11.24|
|Wall St. target price||$12.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-8.03%|
|3 months (2021-05-03)||4.23%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Ironwood Pharmaceuticals shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $193.5 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$398.4 million|
|Operating margin TTM||48.04%|
|Gross profit TTM||$298.3 million|
|Return on assets TTM||23.85%|
|Return on equity TTM||0%|
|Market capitalisation||$2.2 billion|
TTM: trailing 12 months
There are currently 19.6 million Ironwood Pharmaceuticals shares held short by investors – that's known as Ironwood Pharmaceuticals's "short interest". This figure is 1.9% down from 19.9 million last month.
There are a few different ways that this level of interest in shorting Ironwood Pharmaceuticals shares can be evaluated.
Ironwood Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ironwood Pharmaceuticals shares currently shorted divided by the average quantity of Ironwood Pharmaceuticals shares traded daily (recently around 2.1 million). Ironwood Pharmaceuticals's SIR currently stands at 9.36. In other words for every 100,000 Ironwood Pharmaceuticals shares traded daily on the market, roughly 9360 shares are currently held short.
However Ironwood Pharmaceuticals's short interest can also be evaluated against the total number of Ironwood Pharmaceuticals shares, or, against the total number of tradable Ironwood Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ironwood Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Ironwood Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1368% of the tradable shares (for every 100,000 tradable Ironwood Pharmaceuticals shares, roughly 137 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ironwood Pharmaceuticals.
Find out more about how you can short Ironwood Pharmaceuticals stock.
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $8.63 up to $13.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.3406. This would suggest that Ironwood Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.